drugset / Trial / NCT07678684
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HF1K16 | Unknown | — | Intravenous |